Aug. 12 at 7:23 PM
$LENZ - The published Q2 transcript shows no question from Piper Sandler’s Biren Amin. Not one.
The next morning, he cut his target from
$12 to
$7.
This is the analyst who saw
$67 when LENZ traded at
$46.25, then gradually discovered
$62,
$39,
$12 and finally
$7 as the share price collapsed.
WallStreetZen ranks him in the **bottom 6% of analysts**, with a –3.39% average return and a 42% win rate. Apparently the market was expected to overlook that distinguished record.
At
$7, LENZ’s implied equity value is roughly equal to its
$220M Q2 cash balance—assigning essentially nothing to an FDA-approved product protected through 2044+, validated refill cohorts, Telehealth access or international economics.
Perhaps his unpublished model proves commercial failure. Splendid. Publish it.
Until then, this is not price discovery. It is yesterday’s chart dressed up as tomorrow’s analysis.
